Atlas Trials

Propranolol in Combination With Pembrolizumab and Standard Chemotherapy for the Treatment of Unresectable Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Adenocarcinoma

Clinical trial NCT05651594 · RECRUITING

Trial details

NCT number
NCT05651594
Sponsor
Roswell Park Cancer Institute
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Clinical Stage II Esophageal Adenocarcinoma AJCC v8Clinical Stage III Esophageal Adenocarcinoma AJCC v8Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IV Esophageal Adenocarcinoma AJCC v8Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8Locally Advanced Esophageal AdenocarcinomaLocally Advanced Gastroesophageal Junction AdenocarcinomaMetastatic Esophageal AdenocarcinomaMetastatic Gastroesophageal Junction AdenocarcinomaUnresectable Esophageal AdenocarcinomaUnresectable Gastroesophageal Junction Adenocarcinoma
Start date
2023-03-07
Primary completion
2029-03-30
Enrollment
40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.